Cabaletta Bio, INC 8-K filings

Cabaletta Bio announced second quarter 2026 financial results, detailing progress in its rese-cel clinical development program for autoimmune diseases and providing updates on manufacturing partnerships.

Cabaletta Bio, Inc. announced at its Annual Meeting of Stockholders the approval to increase authorized common stock from 300 million to 600 million shares.

Cabaletta Bio announced new clinical data for its rese-cel therapy across multiple autoimmune diseases, highlighting encouraging early findings for preconditioning-free lupus treatment and strong results in myositis and systemic sclerosis.

Cabaletta Bio announced first quarter 2026 financial results, highlighting progress in its rese-cel clinical trials and a new commercial supply agreement with Cellares.

Cabaletta Bio announced new clinical and translational data for rese-cel, showcasing preconditioning-free treatment and automated manufacturing advancements.

Cabaletta Bio announced the pricing of an underwritten offering of 51,725,000 shares of common stock, raising approximately $150 million in gross proceeds.

Cabaletta Bio announced new clinical and translational data from its RESET-PV trial, showing positive activity and tolerability of rese-cel without preconditioning.

Cabaletta Bio shared an updated corporate presentation on April 20, 2026, highlighting progress in its autoimmune disease pipeline, particularly with its lead candidate, rese-cel.

Cabaletta Bio announced its Q4 and full-year 2025 financial results and provided updates on its rese-cel clinical programs and manufacturing innovations.

Cabaletta Bio announced its 2026 strategic priorities, focusing on advancing its rese-cel CAR T therapy through registrational trials, automated manufacturing, and expanded clinical experience for autoimmune diseases.

Cabaletta Bio reports positive clinical data for its rese-cel CAR T therapy in autoimmune diseases, secures key regulatory designations, and outlines a path to BLA submission by 2027, alongside its third-quarter 2025 financial results.

Cabaletta Bio announces significant clinical progress and FDA alignment for its rese-cel CAR T therapy across multiple autoimmune diseases, targeting a 2027 BLA submission for Myositis.

Cabaletta Bio announced positive clinical data and development updates for its rese-cel therapy across multiple autoimmune disease trials, reinforcing its potential for durable, drug-free responses.

Cabaletta Bio reports positive early clinical and translational data for rese-cel in pemphigus vulgaris patients without preconditioning.

Cabaletta Bio provides an updated corporate presentation highlighting significant progress in its rese-cel CAR T-cell therapy program for autoimmune diseases, including FDA alignment for registrational trials and a planned 2027 BLA submission for myositis.

Cabaletta Bio reported Q2 2025 financial results and significant progress in its rese-cel clinical program, including FDA alignment for a 2027 BLA submission in myositis and an extended cash runway.

Cabaletta Bio, a clinical-stage biotechnology company, announced the pricing of a public offering of common stock and warrants, expected to raise approximately $100 million to advance its lead cell therapy candidate, rese-cel, and extend its cash runway into the second half of 2026.

Cabaletta Bio announced compelling new clinical and translational data for its lead investigational therapy, rese-cel, across multiple autoimmune disease trials, alongside the termination of its At-The-Market (ATM) equity program.

Cabaletta Bio, Inc. announced that its stockholders approved an amendment to increase authorized common stock from 150 million to 300 million shares, along with the election of directors and other key proposals at its Annual Meeting on June 9, 2025.

Cabaletta Bio's Board of Directors approved the repricing of underwater stock options for employees, directors, and consultants to incentivize retention through a critical company stage.

Cabaletta Bio plans to submit a Biologics License Application (BLA) for rese-cel in myositis in 2027 after aligning with the FDA on registrational cohort designs.

Cabaletta Bio announces its Q4 and full year 2024 financial results, highlighting progress in its clinical programs and providing a business update.

Cabaletta Bio reports deepening clinical responses with its rese-cel therapy in SLE, LN, and dermatomyositis patients, with many discontinuing immunosuppressants and steroids.

Cabaletta Bio reports positive clinical data for rese-cel, showing deepening clinical responses across multiple autoimmune indications with a favorable safety profile.

Cabaletta Bio announced its cash position of $164 million as of December 31, 2024, will fund operations into the first half of 2026, along with pipeline advancements and strategic priorities for 2025.

Cabaletta Bio reports promising clinical data for CABA-201, showing potential for drug-free responses in autoimmune patients across multiple trials.

Cabaletta Bio reported its third quarter 2024 financial results, highlighted by clinical trial progress and expansion into Europe, with cash runway extended into the first half of 2026.

Cabaletta Bio announced an updated corporate presentation detailing clinical trial progress and upcoming data presentations for its CABA-201 CAR T-cell therapy.

Cabaletta Bio has amended its lease agreement, committing to office and laboratory space through August 2026 in exchange for discounted rental rates.

Cabaletta Bio reported its second quarter 2024 financial results and provided a business update, highlighting progress in its clinical programs and manufacturing strategy.